ACAD Stock Annual Balance Sheet. Download in Excel
ACADIA Pharmaceuticals Inc.
ACAD 
NGS
Sector: Healthcare
Industry: Biotechnology
22.30
USD
0.32
(1.46%)
Previous close: 21.98 Open: 22.3 Bid: 21.88 Ask: 22.3
52 week range
13.40 25.23
Mkt Cap: 3,679 M Avg Vol (90 Days): 2,060,609
Last updated: Tuesday 10th June 2025
Financials
ACAD Balance Sheet
Annual
| Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | Dec-23 | Dec-24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Accounts payable | 2 M | 4 M | 9 M | 3 M | 7 M | 8 M | 7 M | 13 M | 18 M | 16 M |
| Accounts receivable | 6 M | 17 M | 26 M | 36 M | 48 M | 64 M | 62 M | 98 M | 99 M | |
| Accrued expenses | 22 M | 40 M | 49 M | 60 M | 75 M | 106 M | 96 M | 126 M | 254 M | 395 M |
| AccruedInterestReceivable | 2 M | 1 M | 1 M | 2 M | 2 M | 2 M | 978000.0 | 885000.0 | 4 M | 6 M |
| Accumulated depreciation & depletion | -3 M | -3 M | -4 M | -4 M | -5 M | -4 M | -6 M | -8 M | -10 M | -10 M |
| Additional paid in capital | 862 M | 1,452 M | 1,559 M | 1,948 M | 2,403 M | 2,613 M | 2,695 M | 2,771 M | 2,863 M | 2,937 M |
| Cash and equivalents | 103 M | 166 M | 69 M | 135 M | 190 M | 326 M | 147 M | 115 M | 189 M | 320 M |
| CashCashEquivalentsAndShortTermInvestments | 216 M | 531 M | 341 M | 474 M | 697 M | 642 M | 529 M | 423 M | 475 M | 756 M |
| CashEquivalents | 375000.0 | 2 M | 72 M | 140 M | 194 M | 332 M | ||||
| Common par | 10000.0 | 12000.0 | 12000.0 | 14000.0 | 15000.0 | 16000.0 | 16000.0 | 16000.0 | 16000.0 | 16000.0 |
| Common stock equity | 200 M | 518 M | 335 M | 479 M | 699 M | 627 M | 541 M | 400 M | 432 M | 733 M |
| CommonStock | 10000.0 | 12000.0 | 12000.0 | 14000.0 | 15000.0 | 16000.0 | 16000.0 | 16000.0 | 16000.0 | 16000.0 |
| CurrentAccruedExpenses | 20 M | 36 M | 40 M | 56 M | 68 M | 97 M | 89 M | 113 M | 237 M | 379 M |
| CurrentCapitalLeaseObligation | 3 M | 3 M | 3 M | 5 M | 3 M | 5 M | 8 M | 9 M | 9 M | 10 M |
| CurrentDeferredRevenue | 3 M | |||||||||
| CurrentDeferredTaxesAssets | 1 M | 7 M | 9 M | |||||||
| Deferred revenues | 3 M | |||||||||
| DerivativeProductLiabilities | 603000.0 | 898000.0 | 5 M | |||||||
| Finished goods | 2 M | 1 M | 1 M | 3 M | 1 M | 1 M | 2 M | 5 M | 20 M | |
| Float term debt | 6 M | 44 M | 56 M | 53 M | 48 M | 42 M | ||||
| GoodwillAndOtherIntangibleAssets | 7 M | 6 M | 4 M | 3 M | 1 M | 65 M | 120 M | |||
| Gross fixed assets (Plant Property & Equipment) | 5 M | 6 M | 7 M | 8 M | 18 M | 60 M | 72 M | 70 M | 66 M | 61 M |
| Intangibles | 7 M | 6 M | 4 M | 3 M | 1 M | 65 M | 120 M | |||
| Inventories | 4 M | 5 M | 4 M | 6 M | 10 M | 6 M | 5 M | 5 M | 70 M | |
| InventoriesAdjustmentsAllowances | -700000.0 | -3 M | -1 M | -400000.0 | -1 M | -600000.0 | -900000.0 | -500000.0 | ||
| Invested capital | 200 M | 518 M | 335 M | 479 M | 705 M | 671 M | 597 M | 453 M | 480 M | 775 M |
| LongTermCapitalLeaseObligation | 6 M | 44 M | 56 M | 53 M | 48 M | 42 M | ||||
| LongTermDebtAndCapitalLeaseObligation | 6 M | 44 M | 56 M | 53 M | 48 M | 42 M | ||||
| Net fixed assets (net PP&E) | 2 M | 3 M | 3 M | 3 M | 13 M | 56 M | 66 M | 62 M | 56 M | 51 M |
| Non-current deferred income taxes | -3 M | -13 M | -14 M | -13 M | -12 M | -11 M | ||||
| NonCurrentDeferredTaxesAssets | 201 M | 227 M | 238 M | 271 M | 373 M | 393 M | 431 M | 494 M | 494 M | 466 M |
| Other current assets | 2 M | 3 M | 2 M | 5 M | 7 M | 10 M | 14 M | 19 M | 37 M | 38 M |
| Other equity adjustments | 11000.0 | 106000.0 | -399000.0 | -372000.0 | 297000.0 | 36000.0 | ||||
| Other fixed assets | 13 M | 56 M | 66 M | 62 M | 56 M | 51 M | ||||
| Other non-current assets | 329000.0 | 785000.0 | 3 M | 7 M | 8 M | 7 M | 10 M | 13 M | 6 M | 9 M |
| Other non-current liabilities | 2 M | 3 M | 5 M | 7 M | 9 M | 15 M | 18 M | |||
| Other receivable | 517 M | 726 M | 958 M | |||||||
| OtherCurrentLiabilities | 21 M | 26 M | 26 M | 28 M | 43 M | 37 M | ||||
| OtherEquityAdjustments | 493145.0 | |||||||||
| OtherInventories | 6 M | 10 M | 6 M | 5 M | 5 M | 70 M | ||||
| Payables | 2 M | 4 M | 9 M | 3 M | 7 M | 8 M | 7 M | 13 M | 18 M | 16 M |
| Preferred securities of subsidiary trust | 5 M | |||||||||
| PreferredStock | 5 M | |||||||||
| Prepaid expenses | 2 M | 8 M | 8 M | 21 M | 19 M | 26 M | 24 M | 21 M | 39 M | 56 M |
| Raw materials | 2 M | 4 M | 2 M | 1 M | 2 M | 6 M | 5 M | 31 M | 70 M | |
| Retained earnings | -663 M | -934 M | -1,224 M | -1,469 M | -1,704 M | -1,986 M | -2,154 M | -2,371 M | -2,431 M | -2,204 M |
| Total assets | 222 M | 561 M | 385 M | 540 M | 783 M | 783 M | 700 M | 588 M | 749 M | 1,188 M |
| Total current assets | 219 M | 548 M | 373 M | 526 M | 760 M | 718 M | 618 M | 508 M | 616 M | 938 M |
| Total current liabilities | 22 M | 43 M | 49 M | 60 M | 75 M | 106 M | 96 M | 126 M | 254 M | 395 M |
| Total equity | 200 M | 518 M | 335 M | 479 M | 699 M | 627 M | 541 M | 400 M | 432 M | 733 M |
| Total liabilities | 22 M | 43 M | 49 M | 61 M | 84 M | 156 M | 159 M | 187 M | 317 M | 455 M |
| Total non-current assets | 3 M | 11 M | 11 M | 14 M | 23 M | 65 M | 76 M | 75 M | 128 M | 249 M |
| Total non-current liabilities | 232000.0 | 157000.0 | 191000.0 | 2 M | 9 M | 50 M | 63 M | 62 M | 63 M | 60 M |
| TotalEquityGrossMinority | 200 M | 518 M | 335 M | 479 M | 699 M | 627 M | 541 M | 400 M | 432 M | 733 M |
| TotalEquityGrossMinorityInterest | 200 M | 518 M | 335 M | 479 M | 699 M | 627 M | 541 M | 400 M | 432 M | 733 M |
| TotalLiabilitiesAndTotalEquityGrossMinorityInterest | 222 M | 561 M | 385 M | 540 M | 783 M | 783 M | 700 M | 588 M | 749 M | 1,188 M |
| TotalNonCurrentLiabilitiesNetMinorityInteres | 232000.0 | 157000.0 | 191000.0 | 2 M | 9 M | 50 M | 63 M | 62 M | 63 M | 60 M |
| Work in progress | 483000.0 | 2 M | 6 M | 7 M | 4 M | 4 M | 1 M | |||
| Working capital | 197 M | 505 M | 324 M | 467 M | 685 M | 612 M | 522 M | 382 M | 362 M | 543 M |
| ltinv | 213 M | 523 M | 334 M | 451 M | 623 M | 633 M | 500 M | 396 M | 315 M | 588 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.